Anticancer Drugs Practice Questions

Q: All are true regarding Sunitinib except which of the following?

It is excreted primarily in urine. ***It is excreted primarily in urine*** - **Sunitinib** is predominantly metabolized in the **liver** by CYP3A4 and primarily excreted in the **feces**, not urine. - Its major active metabolite, N-desethyl sunitinib, is also primarily eliminated via the fecal route. *It inhibits tyrosine kinase receptors* - **Sunitinib** is a **multitargeted receptor tyrosine kinase (RTK) inhibitor**. - It blocks several RTKs involved in tumor growth, angiogenesis, and metastatic progression, such as **VEGFR, PDGFR, KIT, and FLT3**. *It is used for the treatment of GIST* - **Sunitinib** is approved for the treatment of **imatinib-refractory** or **imatinib-intolerant gastrointestinal stromal tumors (GIST)**. - Its mechanism in GIST involves inhibiting KIT and PDGFR, which are often mutated and constitutively active in this cancer. *It is used for renal cell carcinoma* - **Sunitinib** is a standard first-line treatment for **advanced renal cell carcinoma (RCC)**. - Its efficacy in RCC is primarily due to its inhibition of VEGFR, which targets the high vascularity characteristic of kidney tumors.

Q: Which of the following anticancer drugs can cause flagellate dermatitis?

Bleomycin. ***Bleomycin*** - **Flagellate dermatitis** is a characteristic skin toxicity of bleomycin, presenting as linear erythematous streaks that resemble whip marks. - This dermatological reaction is thought to be related to the drug's accumulation in the skin, leading to inflammation and hyperpigmentation. *Cisplatin* - Cisplatin is notorious for causing significant **nephrotoxicity** and **ototoxicity**, which are its dose-limiting toxicities. - While it can cause some dermatological side effects, **flagellate dermatitis** is not a common or characteristic adverse effect associated with this drug. *L-asparaginase* - L-asparaginase frequently causes **hypersensitivity reactions** and **pancreatitis** due to its mechanism of depleting asparagine. - Skin toxicities associated with L-asparaginase are typically less common and do not include **flagellate dermatitis**. *Doxorubicin* - Doxorubicin is well-known for its **cardiotoxicity**, leading to dilated cardiomyopathy, and also causes **alopecia** and severe local tissue damage if extravasated. - Although it can cause various skin manifestations, **flagellate dermatitis** is not a typical dermatological toxicity of doxorubicin.

Q: All of these are G2 phase blockers except:

Paclitaxel. ***Paclitaxel*** - **Paclitaxel** is a **microtubule-stabilizing drug** that acts predominantly in the **M phase** of the cell cycle by inhibiting microtubule depolymerization, thereby blocking cell division [1]. - It is known as a **mitotic inhibitor**, specifically preventing the progression from **metaphase to anaphase** [2]. - **NOT a G2 phase blocker** - this is the correct answer. *Etoposide* - **Etoposide** is a **topoisomerase II inhibitor** that causes DNA strand breaks, predominantly acting in the **late S and G2 phases** of the cell cycle [3]. - Its primary effect is to arrest cells in the **G2 phase**, making it a classic **G2 phase blocker** [2]. *Daunorubicin* - **Daunorubicin** is an **anthracycline antibiotic** that intercalates into DNA, leading to DNA damage and inhibition of DNA and RNA synthesis. - It primarily acts in the **S phase** but the resulting DNA damage activates checkpoints leading to **G2 phase arrest**, thus functioning as a G2 blocker [3]. *Topotecan* - **Topotecan** is a **topoisomerase I inhibitor**, which prevents DNA unwinding and replication by stabilizing the topoisomerase I-DNA complex, leading to DNA strand breaks. - Its main effect is in the **S phase**, but the DNA damage induces cell cycle arrest in the **G2 phase** through checkpoint activation [3].

Q: Which of the following is not an alkylating agent?

Cladrabine. ***Cladrabine*** - **Cladrabine** is a **purine analog**, which is a type of antimetabolite, not an alkylating agent. - It works by being incorporated into DNA, leading to **DNA strand breaks** and inhibition of DNA synthesis. *Chlorambucil* - **Chlorambucil** is a nitrogen mustard derivative, which is a classic **alkylating agent**. - It forms **covalent bonds** with DNA, primarily at guanine bases, cross-linking DNA strands and inhibiting replication. *Ifosfamide* - **Ifosfamide** belongs to the **oxazaphosphorine** class of alkylating agents, similar to cyclophosphamide. - It also works by forming **DNA cross-links**, which interferes with DNA replication and transcription. *Nitrosurea* - **Nitrosureas** (e.g., carmustine, lomustine) are a class of alkylating agents that can cross the **blood-brain barrier**. - They act by **alkylating DNA** and RNA, inducing interstrand and intrastrand cross-links, and inhibiting DNA repair.

Q: Which of the following drugs is not used in prostate carcinoma?

Testosterone. ***Testosterone*** - **Testosterone** is an **androgen** that promotes the growth and progression of prostate cancer. - Administering testosterone would worsen prostate carcinoma and is therefore contraindicated [2]. *Finasteride* - **Finasteride** is a **5-alpha-reductase inhibitor** that blocks the conversion of testosterone to dihydrotestosterone (DHT), the more potent androgen responsible for prostate growth [1]. - It is used in prostate cancer management to reduce androgen-dependent tumor growth, as DHT stimulates the proliferation of prostate cancer cells. *Diethylstilbestrol* - **Diethylstilbestrol (DES)** is a **synthetic estrogen** that works by suppressing the production of testosterone from the testes through negative feedback on the hypothalamus and pituitary gland [4]. - While historically used, its use has largely been replaced by newer, more targeted therapies due to its significant side effects [4]. *Flutamide* - **Flutamide** is an **anti-androgen** that acts by competitively blocking androgen receptors in prostate cancer cells [3]. - It prevents testosterone and DHT from binding to their receptors, thereby inhibiting androgen-dependent tumor growth without affecting androgen production [3].

Q: Which of the following is not an early adverse effect of methotrexate?

Hepatic fibrosis. ***Hepatic fibrosis*** - **Hepatic fibrosis** is a *late-onset* adverse effect of **methotrexate** therapy, developing after prolonged use (months to years), rather than in the early stages. [2] - This complication is associated with cumulative doses and pre-existing liver conditions, requiring long-term monitoring rather than immediate concern after starting treatment. [1] *Myelosuppression* - **Myelosuppression** (bone marrow suppression) can occur relatively *early* in methotrexate treatment due to its impact on rapidly dividing cells, including hematopoietic stem cells. [1] - This can lead to **leukopenia**, **anemia**, or **thrombocytopenia**, necessitating close monitoring of blood counts. [2] *Nausea* - **Nausea** is a common *acute* gastrointestinal side effect that frequently occurs within hours or days of methotrexate administration. [3] - It results from the drug's effect on the gastrointestinal tract and can often be mitigated with antiemetics or dose adjustments. *Stomatitis* - **Stomatitis** (inflammation of the mouth lining) is another frequent and *early* adverse effect, often appearing within a few days of methotrexate exposure. [1], [2] - It is caused by the *antimetabolite* action of methotrexate on rapidly dividing oral mucosal cells, leading to painful ulcers.

Q: Which of the following is used to treat hormone-responsive breast cancer?

Tamoxifen. ***Tamoxifen*** - **Tamoxifen** is a **selective estrogen receptor modulator (SERM)** that acts as an **estrogen antagonist** in breast tissue, thereby blocking estrogen's proliferative effects on breast cancer cells. - It is a cornerstone treatment for **hormone-responsive (estrogen receptor-positive, ER+) breast cancer**, both in early and advanced stages, and can also be used for prevention in high-risk individuals. *Cyproterone acetate* - **Cyproterone acetate** is an **anti-androgen** with progestational activity, primarily used in conditions like **hirsutism**, prostate cancer, and severe acne. - While it has hormonal activity, it is not a primary therapeutic agent for **hormone-responsive breast cancer**. *Clomiphene citrate* - **Clomiphene citrate** is an **estrogen receptor modulator** used to induce ovulation in women who are anovulatory or oligo-ovulatory. - It works by blocking estrogen receptors in the hypothalamus, leading to increased release of **gonadotropins**, and is not used in breast cancer treatment. *Diethylstibestrol* - **Diethylstilbestrol (DES)** is a **synthetic non-steroidal estrogen** that was historically used for various conditions, including preventing miscarriage, but was later found to have significant adverse effects and teratogenic risks. - It was used as a treatment for advanced prostate cancer and, in very specific circumstances, even for breast cancer in postmenopausal women, but it is **not a current first-line therapy** for hormone-responsive breast cancer due to its toxicity and the availability of safer, more effective drugs.

Q: A 70-year-old male presented with lumps felt in the axilla. On examination, axillary lymphadenopathy was noted. Biopsy was planned with the following histopathological examination. No Reed-Sternberg cells were seen. Flow cytometry revealed CD15 and CD30 negative. Following the histopathological confirmation of the disease, the patient was started on a chemotherapy regimen. After a few days, the patient developed dysuria. Which drug could have been supplemented to prevent hemorrhagic cystitis associated with the chemotherapy?

Mesna. ***Mesna*** - **Mesna** (2-mercaptoethane sulfonate sodium) is a chemoprotective agent used to prevent **hemorrhagic cystitis** caused by **cyclophosphamide** and **ifosfamide**. - In this case, the patient with non-Hodgkin lymphoma (CD15/CD30 negative, no Reed-Sternberg cells) was likely treated with a **cyclophosphamide-containing regimen** such as **CHOP** or **R-CHOP**. - Mesna works by **detoxifying acrolein**, a nephrotoxic and urotoxic metabolite of cyclophosphamide, in the urinary tract, thereby preventing bladder mucosal damage. *Acrolein* - **Acrolein** is the **toxic metabolite** of cyclophosphamide and ifosfamide that causes damage to the bladder lining, leading to hemorrhagic cystitis. - It is not a drug but the substance that needs to be neutralized by mesna. *Dexrazoxane* - **Dexrazoxane** is a cardioprotective agent used to prevent **anthracycline-induced cardiotoxicity**, specifically from drugs like **doxorubicin**. - It chelates iron and reduces oxidative damage to cardiomyocytes but does not prevent hemorrhagic cystitis. *Amifostine* - **Amifostine** is a cytoprotective agent used to reduce **cisplatin-induced nephrotoxicity** and **xerostomia** in patients undergoing radiation therapy for head and neck cancer. - It is not indicated for the prevention of hemorrhagic cystitis.

Q: Which of the following is an alkylating agent used in cancer treatment?

Chlorambucil. ***Chlorambucil*** - **Chlorambucil** is a classic example of an **alkylating agent** used in chemotherapy. - Alkylating agents work by forming **covalent bonds** with DNA, leading to DNA damage and ultimately cell death. - It is particularly used in chronic lymphocytic leukemia and lymphomas. *Actinomycin-D* - **Actinomycin-D** is an **antibiotic** that functions as an **intercalating agent**, inhibiting RNA synthesis. - It works by inserting itself between DNA base pairs, distorting the DNA structure and preventing transcription. *5-Fluorouracil* - **5-Fluorouracil (5-FU)** is an **antimetabolite**, specifically a pyrimidine analog. - It interferes with DNA synthesis by mimicking **uracil** and inhibiting **thymidylate synthase**. *Vincristine* - **Vincristine** is a **vinca alkaloid**, a type of **microtubule inhibitor**. - It prevents the formation of the **mitotic spindle**, thereby arresting cells in metaphase and inhibiting cell division.

Q: What is the most important target of action of chlorambucil?

Lymphoid tissue. ***Lymphoid tissue*** - **Chlorambucil** is an **alkylating agent** primarily used in the treatment of various **lymphoproliferative disorders**. - Its main therapeutic effect is on rapidly proliferating cells, particularly those of **lymphoid origin**, such as in chronic lymphocytic leukemia (CLL) and other lymphomas. *Myeloid tissue* - While chlorambucil can have some effect on myeloid cells, it is not its primary or most important target; other drugs are more specifically used for **myeloproliferative disorders**. - Its use in conditions like chronic myeloid leukemia (CML) is limited and generally not first-line. *Neural tissue* - Chlorambucil is not primarily an agent targeting **neural tissue** and is not used in the treatment of neurological conditions. - It does not readily cross the **blood-brain barrier** to a significant extent, limiting its direct action on the central nervous system. *Skin* - Although some **lymphomas** can manifest with **cutaneous involvement**, chlorambucil's direct and most important target is not the skin itself but rather the underlying **lymphoid cells**. - It is not a primary treatment for general skin conditions or non-lymphomatous skin cancers.

Question 1

All are true regarding Sunitinib except which of the following?

Accepted Answer

It is excreted primarily in urine

Answer

It inhibits tyrosine kinase receptors

Answer

It is used for the treatment of GIST

Answer

It is used for renal cell carcinoma

Question 2

Which of the following anticancer drugs can cause flagellate dermatitis?

Accepted Answer

Bleomycin

Answer

Cisplatin

Answer

L-asparaginase

Answer

Doxorubicin

Question 3

All of these are G2 phase blockers except:

Accepted Answer

Paclitaxel

Answer

Daunorubicin

Answer

Etoposide

Answer

Topotecan

Question 4

Which of the following is not an alkylating agent?

Accepted Answer

Cladrabine

Answer

Chlorambucil

Answer

Ifosfamide

Answer

Nitrosurea

Question 5

Which of the following drugs is not used in prostate carcinoma?

Accepted Answer

Testosterone

Answer

Diethylstilbestrol

Answer

Flutamide

Answer

Finasteride

Question 6

Which of the following is not an early adverse effect of methotrexate?

Accepted Answer

Hepatic fibrosis

Answer

Myelosuppression

Answer

Nausea

Answer

Stomatitis

Question 7

Which of the following is used to treat hormone-responsive breast cancer?

Accepted Answer

Tamoxifen

Answer

Clomiphene citrate

Answer

Diethylstibestrol

Answer

Cyproterone acetate

Question 8

A 70-year-old male presented with lumps felt in the axilla. On examination, axillary lymphadenopathy was noted. Biopsy was planned with the following histopathological examination. No Reed-Sternberg cells were seen. Flow cytometry revealed CD15 and CD30 negative. Following the histopathological confirmation of the disease, the patient was started on a chemotherapy regimen. After a few days, the patient developed dysuria. Which drug could have been supplemented to prevent hemorrhagic cystitis associated with the chemotherapy?

Accepted Answer

Mesna

Answer

Acrolein

Answer

Dexrazoxane

Answer

Amifostine

Question 9

Which of the following is an alkylating agent used in cancer treatment?

Accepted Answer

Chlorambucil

Answer

Actinomycin-D

Answer

5-Fluorouracil

Answer

Vincristine

Question 10

What is the most important target of action of chlorambucil?

Accepted Answer

Lymphoid tissue

Answer

Myeloid tissue

Answer

Neural tissue

Answer

Skin

Anticancer Drugs — MCQs

Anticancer Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?